Results of a phase 1 UCART19 trial, a first-in-class allogeneic anti-CD19 CART-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM) published in The Lancet Haematology
The prognosis for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia remains poor. UCART19, an allogeneic genome-edited anti-CD19 chimeric antigen receptor (CAR) T-cell product derived from healthy donors and available for immediate clinical use, offers a potential therapeutic option for such patients. The CALM trial is a first-in-human study evaluating the safety and antileukaemic